Dermatologic drugs in pregnancy
Identifieur interne : 002F41 ( Main/Exploration ); précédent : 002F40; suivant : 002F42Dermatologic drugs in pregnancy
Auteurs : Monica Bologa [Canada] ; Anne Pastuszak [Canada] ; Neil H. Shear [Canada] ; Gideon Koren [Canada]Source :
- Clinics in Dermatology [ 0738-081X ] ; 1991.
English descriptors
- Teeft :
- Acetylsalicylic acid, Acitretin, Acne, Acyclovir, Adverse effects, Animal studies, Antihistamine, Antimalarial, Antimicrobial, Appl, Appl pharmacol, Baseline, Baseline risk, Birth defects, Bologa, Bologa clinics, Boric acid, Case report, Case reports, Chemotherapy, Chloroquine, Cleft, Cleft palate, Clin, Clin pharmacol, Clindamycin, Clinic, Clinical pharmacology, Congenital, Congenital defects, Congenital malformations, Corticosteroid, Defect, Dermatol, Dermatologic, Dermatology, Dermatology dermatologic, Dos, Early pregnancy, Elective abortions, Erythromycin, Etretinate, Experimental studies, Fatal poisoning, Fetal, Fetal development, Fetus, First trimester, General population, Gentamicin, Gestation, Gestational exposure, Griseofulvin, Gynecol, Hexachlorophene, High doses, Human reports, Human teratogenicity, Hydroxyzine, Inadvertent, Inadvertent exposure, Intrauterine exposure, Isotretinoin, Ketoconazole, Lancet, Large categories, Late pregnancy, Liveborn infants, Major malformations, Malformation, Malformation rate, Malformed infants, Maternal ingestion, Methotrexate, Miconazole, Minor malformations, Motherisk program, Mucous membranes, Multiple malformations, Mycosis fungoides, Neonatal, Neonate, Obstet, Obstet gynecol, Palate, Pediatr, Penicillin, Percutaneous, Percutaneous absorption, Pharmacol, Placenta, Placental transfer, Potential risk, Pregnancy, Pregnant patient, Pregnant women, Prospective study, Psoriasis, Relative risk, Reproductive, Reproductive toxicity, Retinoid, Retinol, Rheumatoid arthritis, Salicylic acid, Severe psoriasis, Sick children, Significant association, Spontaneous abortions, Sulfonamide, Teratogen, Teratogenic, Teratogenic effects, Teratogenic risk, Teratogenicity, Teratological studies, Teratology, Tetracycline, Third trimesters, Topical, Topical application, Topical preparations, Topically, Toxicity, Trimester, Ultrasound, Utero, Utero exposure, Vulvovaginal candidiasis, Warrant pregnancy termination.
Abstract
Abstract: Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,1 use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.2,3 Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-cis-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.4
Url:
DOI: 10.1016/0738-081X(91)90072-S
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000297
- to stream Istex, to step Curation: 000297
- to stream Istex, to step Checkpoint: 001D12
- to stream Main, to step Merge: 003008
- to stream Main, to step Curation: 002F41
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Dermatologic drugs in pregnancy</title><author><name sortKey="Bologa, Monica" sort="Bologa, Monica" uniqKey="Bologa M" first="Monica" last="Bologa">Monica Bologa</name></author><author><name sortKey="Pastuszak, Anne" sort="Pastuszak, Anne" uniqKey="Pastuszak A" first="Anne" last="Pastuszak">Anne Pastuszak</name></author><author><name sortKey="Shear, Neil H" sort="Shear, Neil H" uniqKey="Shear N" first="Neil H." last="Shear">Neil H. Shear</name></author><author><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:13EC5A1437D79446E780E3FDFC85FA1230D537CF</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0738-081X(91)90072-S</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-1M4MK031-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000297</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000297</idno><idno type="wicri:Area/Istex/Curation">000297</idno><idno type="wicri:Area/Istex/Checkpoint">001D12</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D12</idno><idno type="wicri:doubleKey">0738-081X:1991:Bologa M:dermatologic:drugs:in</idno><idno type="wicri:Area/Main/Merge">003008</idno><idno type="wicri:Area/Main/Curation">002F41</idno><idno type="wicri:Area/Main/Exploration">002F41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Dermatologic drugs in pregnancy</title><author><name sortKey="Bologa, Monica" sort="Bologa, Monica" uniqKey="Bologa M" first="Monica" last="Bologa">Monica Bologa</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children</wicri:regionArea><wicri:noRegion>Hospital for Sick Children</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Currently with The Upjohn Company of Canada</wicri:regionArea></affiliation></author><author><name sortKey="Pastuszak, Anne" sort="Pastuszak, Anne" uniqKey="Pastuszak A" first="Anne" last="Pastuszak">Anne Pastuszak</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children</wicri:regionArea><wicri:noRegion>Hospital for Sick Children</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Shear, Neil H" sort="Shear, Neil H" uniqKey="Shear N" first="Neil H." last="Shear">Neil H. Shear</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children</wicri:regionArea><wicri:noRegion>Hospital for Sick Children</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Career Scientists at the Ontario Ministry of Health</wicri:regionArea></affiliation></author><author><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Address correspondence to: Gideon Koren, MD, FRPC, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8</wicri:regionArea><wicri:noRegion>Ontario M5G 1X8</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children</wicri:regionArea><wicri:noRegion>Hospital for Sick Children</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Career Scientists at the Ontario Ministry of Health</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinics in Dermatology</title><title level="j" type="abbrev">CID</title><idno type="ISSN">0738-081X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="435">435</biblScope><biblScope unit="page" to="451">451</biblScope></imprint><idno type="ISSN">0738-081X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0738-081X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acetylsalicylic acid</term><term>Acitretin</term><term>Acne</term><term>Acyclovir</term><term>Adverse effects</term><term>Animal studies</term><term>Antihistamine</term><term>Antimalarial</term><term>Antimicrobial</term><term>Appl</term><term>Appl pharmacol</term><term>Baseline</term><term>Baseline risk</term><term>Birth defects</term><term>Bologa</term><term>Bologa clinics</term><term>Boric acid</term><term>Case report</term><term>Case reports</term><term>Chemotherapy</term><term>Chloroquine</term><term>Cleft</term><term>Cleft palate</term><term>Clin</term><term>Clin pharmacol</term><term>Clindamycin</term><term>Clinic</term><term>Clinical pharmacology</term><term>Congenital</term><term>Congenital defects</term><term>Congenital malformations</term><term>Corticosteroid</term><term>Defect</term><term>Dermatol</term><term>Dermatologic</term><term>Dermatology</term><term>Dermatology dermatologic</term><term>Dos</term><term>Early pregnancy</term><term>Elective abortions</term><term>Erythromycin</term><term>Etretinate</term><term>Experimental studies</term><term>Fatal poisoning</term><term>Fetal</term><term>Fetal development</term><term>Fetus</term><term>First trimester</term><term>General population</term><term>Gentamicin</term><term>Gestation</term><term>Gestational exposure</term><term>Griseofulvin</term><term>Gynecol</term><term>Hexachlorophene</term><term>High doses</term><term>Human reports</term><term>Human teratogenicity</term><term>Hydroxyzine</term><term>Inadvertent</term><term>Inadvertent exposure</term><term>Intrauterine exposure</term><term>Isotretinoin</term><term>Ketoconazole</term><term>Lancet</term><term>Large categories</term><term>Late pregnancy</term><term>Liveborn infants</term><term>Major malformations</term><term>Malformation</term><term>Malformation rate</term><term>Malformed infants</term><term>Maternal ingestion</term><term>Methotrexate</term><term>Miconazole</term><term>Minor malformations</term><term>Motherisk program</term><term>Mucous membranes</term><term>Multiple malformations</term><term>Mycosis fungoides</term><term>Neonatal</term><term>Neonate</term><term>Obstet</term><term>Obstet gynecol</term><term>Palate</term><term>Pediatr</term><term>Penicillin</term><term>Percutaneous</term><term>Percutaneous absorption</term><term>Pharmacol</term><term>Placenta</term><term>Placental transfer</term><term>Potential risk</term><term>Pregnancy</term><term>Pregnant patient</term><term>Pregnant women</term><term>Prospective study</term><term>Psoriasis</term><term>Relative risk</term><term>Reproductive</term><term>Reproductive toxicity</term><term>Retinoid</term><term>Retinol</term><term>Rheumatoid arthritis</term><term>Salicylic acid</term><term>Severe psoriasis</term><term>Sick children</term><term>Significant association</term><term>Spontaneous abortions</term><term>Sulfonamide</term><term>Teratogen</term><term>Teratogenic</term><term>Teratogenic effects</term><term>Teratogenic risk</term><term>Teratogenicity</term><term>Teratological studies</term><term>Teratology</term><term>Tetracycline</term><term>Third trimesters</term><term>Topical</term><term>Topical application</term><term>Topical preparations</term><term>Topically</term><term>Toxicity</term><term>Trimester</term><term>Ultrasound</term><term>Utero</term><term>Utero exposure</term><term>Vulvovaginal candidiasis</term><term>Warrant pregnancy termination</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,1 use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.2,3 Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-cis-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.4</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Bologa, Monica" sort="Bologa, Monica" uniqKey="Bologa M" first="Monica" last="Bologa">Monica Bologa</name></noRegion><name sortKey="Bologa, Monica" sort="Bologa, Monica" uniqKey="Bologa M" first="Monica" last="Bologa">Monica Bologa</name><name sortKey="Bologa, Monica" sort="Bologa, Monica" uniqKey="Bologa M" first="Monica" last="Bologa">Monica Bologa</name><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><name sortKey="Pastuszak, Anne" sort="Pastuszak, Anne" uniqKey="Pastuszak A" first="Anne" last="Pastuszak">Anne Pastuszak</name><name sortKey="Pastuszak, Anne" sort="Pastuszak, Anne" uniqKey="Pastuszak A" first="Anne" last="Pastuszak">Anne Pastuszak</name><name sortKey="Shear, Neil H" sort="Shear, Neil H" uniqKey="Shear N" first="Neil H." last="Shear">Neil H. Shear</name><name sortKey="Shear, Neil H" sort="Shear, Neil H" uniqKey="Shear N" first="Neil H." last="Shear">Neil H. Shear</name><name sortKey="Shear, Neil H" sort="Shear, Neil H" uniqKey="Shear N" first="Neil H." last="Shear">Neil H. Shear</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:13EC5A1437D79446E780E3FDFC85FA1230D537CF
|texte= Dermatologic drugs in pregnancy
}}
| This area was generated with Dilib version V0.6.33. |  |